Sarepta Therapeutics announced a refinancing deal delaying approximately $700 million in convertible notes until 2030 to bolster its financial standing amid ongoing challenges, including setbacks with its Duchenne muscular dystrophy therapy. The company simultaneously undertook workforce reductions as part of a strategic restructuring. Rocket Pharmaceuticals received FDA approval to resume its pivotal gene therapy trial for Danon disease with a lower dose following a clinical hold. Xoma Royalty’s acquisition spree continued with its purchase of Mural Oncology, expanding its portfolio of struggling biotechs. These developments reflect shifting dynamics in biotech finance and regulatory landscapes influencing pipeline strategies and investor confidence.